GlassScriptPhysician profile
Steven H Mckinley
NPI 1780786491
$4,646.81
in general payments reported to CMS, 2019-2025
27 companies · $1,071 in 2025
The $1,071 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,084 · 2020: $322 · 2021: $14.39 · 2022: $345 · 2023: $643 · 2024: $1,169 · 2025: $1,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,882.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $878.99 | 2022-2025 | |
| New World Medical,INC. | $863.56 | 2019-2025 | Clearpath, Streamline, Kahook Dual Blade |
| Bausch & Lomb Americas INC. | $472.10 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Aerie Pharmaceuticals, INC. | $399.73 | 2019-2020 | |
| Glaukos Corporation | $313.86 | 2019-2024 | |
| Alcon Vision LLC | $248.07 | 2022-2025 | Clareon, Rocklatan |
| Allergan, INC. | $192.34 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $149.93 | 2019-2020 | |
| Ivantis, INC | $148.69 | 2020 | |
| Amgen INC. | $141.77 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $124.38 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $102.81 | 2024-2025 | Xdemvy |
| Optovue, INC. | $100.00 | 2019 | |
| Thea Pharma INC. | $66.87 | 2022-2025 | Iyuzeh |
| Ocular Therapeutix, INC. | $66.01 | 2020-2023 | Dextenza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $65.54 | 2024 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Harrow Eye, LLC | $53.00 | 2024-2025 | Vevye |
| Shire North American Group INC | $44.35 | 2019 | |
| Sun Pharmaceutical Industries INC. | $39.72 | 2024 | |
| Oyster Point Pharma, INC. | $28.15 | 2022 | |
| Mallinckrodt Hospital Products INC. | $24.69 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $24.18 | 2019 | |
| Biotissue Holdings INC. | $23.70 | 2022 | |
| Mallinckrodt Enterprises LLC | $22.93 | 2019 | |
| Rayner Intraocular Lenses Limited | $21.77 | 2023 | Rayone Spheric, Omidria, Rayone Aspheric |
| Tearlab Corp | $15.35 | 2022 | |
| Eyevance Pharmaceuticals LLC | $14.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Mckinley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.